Notice of AGM
Hemogenyx Pharmaceuticals plc has announced the posting of its Annual Report and Accounts for the year ended 31 December 2025, along with the Notice of its Annual General Meeting and a Form of Proxy. These documents will be sent to shareholders and made available on the company's website. The Annual General Meeting is scheduled to take place on 30 June 2026 at 2:00 pm BST.
Select text to share a quote on X · sign in to keep highlights & notes in your HEMO notes
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group, confirms that the Annual Report and Accounts for the year ended 31 December 2025, the Notice of the Annual General Meeting ("AGM") and a Form of Proxy will be posted to shareholders today and will shortly be available on the Company's website at https://hemogenyx.com/investors/annual-half-year-reports/.
The AGM is to be held on 30 June 2026 at 2.00 pm BST at One Heddon Street, London, W1B 4BD.
The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.